WO2010085100A3 - 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 - Google Patents

신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 Download PDF

Info

Publication number
WO2010085100A3
WO2010085100A3 PCT/KR2010/000395 KR2010000395W WO2010085100A3 WO 2010085100 A3 WO2010085100 A3 WO 2010085100A3 KR 2010000395 W KR2010000395 W KR 2010000395W WO 2010085100 A3 WO2010085100 A3 WO 2010085100A3
Authority
WO
WIPO (PCT)
Prior art keywords
transmembrane domain
cellular transmembrane
transduction system
same
system containing
Prior art date
Application number
PCT/KR2010/000395
Other languages
English (en)
French (fr)
Other versions
WO2010085100A2 (ko
Inventor
김재일
박진석
김현진
Original Assignee
광주과학기술원
애니젠 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 광주과학기술원, 애니젠 주식회사 filed Critical 광주과학기술원
Publication of WO2010085100A2 publication Critical patent/WO2010085100A2/ko
Publication of WO2010085100A3 publication Critical patent/WO2010085100A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템에 관한 것이다. 본 발명의 세포막 투과 도메인은 기존의 바이러스로부터 유래된 펩타이드 또는 서열 특이적으로 설계된 펩타이드들과 비교할 때, 유전적인 면역 문제 또는 세포 독성에 있어서 매우 우수한 효과를 나타낼 수 있기 때문에, 부작용의 우려 없이 임상적으로 인체에 적용할 수 있으며, 여러 질병에 관한 진단 및 신약 개발에도 활용할 수 있다.
PCT/KR2010/000395 2009-01-21 2010-01-21 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 WO2010085100A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0004863 2009-01-21
KR1020090004863A KR101169030B1 (ko) 2009-01-21 2009-01-21 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템

Publications (2)

Publication Number Publication Date
WO2010085100A2 WO2010085100A2 (ko) 2010-07-29
WO2010085100A3 true WO2010085100A3 (ko) 2010-11-11

Family

ID=42356331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/000395 WO2010085100A2 (ko) 2009-01-21 2010-01-21 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템

Country Status (2)

Country Link
KR (1) KR101169030B1 (ko)
WO (1) WO2010085100A2 (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013077680A1 (ko) * 2011-11-23 2013-05-30 주식회사 프로셀제약 세포 투과능을 개선한 개량형 신규 거대 분자 전달 도메인 개발 및 이의 이용방법
WO2013169060A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 패혈증 예방 또는 치료용 조성물
CN108949717B (zh) 2012-05-11 2023-06-20 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
US10967000B2 (en) * 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
KR102201430B1 (ko) * 2012-09-19 2021-01-12 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
TWI655204B (zh) 2012-09-19 2019-04-01 韓商傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
JP6517692B2 (ja) 2012-09-19 2019-05-22 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
KR101636542B1 (ko) * 2012-10-09 2016-07-07 한양대학교 산학협력단 인간 ｎｌｂｐ 유래의 ｎｐ12 폴리펩티드 또는 ｎｐ21 폴리펩티드를 포함하는 세포 투과 펩티드 및 이를 이용한 카고 전달 시스템
KR101475744B1 (ko) * 2013-03-08 2014-12-24 서울대학교산학협력단 세포 투과 펩타이드
ES2716870T3 (es) 2013-04-19 2019-06-17 Gemvax & Kael Co Ltd Composición para el tratamiento y prevención de lesión isquémica
KR102166545B1 (ko) 2013-06-21 2020-10-16 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
JP6574175B2 (ja) * 2013-07-12 2019-09-11 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、及びそれを含むコンジュゲート
KR101691479B1 (ko) 2013-10-23 2017-01-02 주식회사 젬백스앤카엘 전립선 비대증 치료 및 예방용 조성물
KR102494803B1 (ko) 2013-11-22 2023-02-06 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
KR102166549B1 (ko) * 2014-01-10 2020-10-16 주식회사 젬백스앤카엘 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
CN106456697B (zh) 2014-04-11 2019-12-17 珍白斯凯尔有限公司 具有纤维化抑制活性的肽和含有其的组合物
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
WO2016006744A1 (ko) * 2014-07-11 2016-01-14 주식회사 프로셀테라퓨틱스 세포 내 분자 전송 펩티드를 이용한 경피 전달용 펩티드-sirna 복합체 및 이의 용도
KR101695792B1 (ko) * 2014-09-04 2017-01-12 디오셀 주식회사 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
JP7000161B2 (ja) 2015-05-26 2022-01-19 ジェムバックス アンド カエル カンパニー，リミティド 新規ペプチド及びこれを含む組成物
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
EP3441082B1 (en) 2016-04-07 2023-06-21 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
KR20210143127A (ko) 2020-05-19 2021-11-26 애니젠 주식회사 신규 뉴클레오린-결합 펩타이드 및 이의 용도
AU2022276988A1 (en) 2021-05-18 2023-09-21 Anygen Co., Ltd. Antiviral composition comprising a nucleolin-binding peptide
WO2023090935A1 (ko) * 2021-11-18 2023-05-25 애니젠 주식회사 뉴클레오린에 특이적으로 결합하는 agm 펩타이드를 제조하는 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154188A1 (en) * 2002-03-29 2005-07-14 Dae-You Kim Cytoplasmic tranduction peptides and uses thereof
KR100859972B1 (ko) * 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154188A1 (en) * 2002-03-29 2005-07-14 Dae-You Kim Cytoplasmic tranduction peptides and uses thereof
KR100859972B1 (ko) * 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABDULRASHEED A. ALABI ET AL.: "Portability of paddle motif function and pharmacology in voltage sensors", NATURE, vol. 450, 15 November 2007 (2007-11-15), pages 370 - 375 *
HOI JONG JUNG ET AL.: "Solution Structure and Lipid Membrane Partitioning of VSTx1, an Inhibitor of the KvAP Potassium Channel", BIOCHEMISTRY, vol. 44, 26 April 2005 (2005-04-26), pages 6015 - 6023 *
YOUXING JIANG ET AL.: "X-ray structure of a voltage-dependent K1+ channel", NATURE, vol. 423, 1 May 2003 (2003-05-01), pages 33 - 41 *

Also Published As

Publication number Publication date
KR101169030B1 (ko) 2012-07-26
KR20100085527A (ko) 2010-07-29
WO2010085100A2 (ko) 2010-07-29

Similar Documents

Publication Publication Date Title
WO2010085100A3 (ko) 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
WO2012038061A3 (en) Nanocapsules containing microemulsions
WO2009108730A3 (en) Forms of rifaximin and uses thereof
WO2010069532A8 (en) Antibodies against human angiopoietin 2
EP3050876A3 (en) Kinase modulators
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
EP2180907A4 (en) Aspiration system for removing liquid discharged by the human body, and liquid sensor therefor
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
WO2010138194A3 (en) Immunomodulatory agent-polymeric compounds
WO2011077043A3 (fr) Derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
WO2009024677A3 (fr) Utilisation d ' acide hyaluronique pour la preparation de compositions destinees a l' amelioration de la fonction de protection de la peau, de l' oeil et des muqueuses
WO2009060097A3 (de) Hygiene- oder pflegeartikel, aufweisend einen anteil an hydroaktiven polymeren, und eine zubereitung aufweisend bakteriophagen oder mindestens einen bestandteil derselben
WO2008141308A3 (en) Gene expression and pain
WO2009121039A3 (en) Administration of benzodiazepine compositions
WO2011106376A3 (en) Use of microvesicles in the treatment of medical conditions
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
WO2009089234A3 (en) Substituted dibenzhydrylpiperazines
WO2010144477A3 (en) Sulfonylurea modulators of endothelin receptor
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2010046061A3 (de) Kosmetische und/oder pharmazeutische zubereitungen
WO2010012940A3 (fr) Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules
WO2011163512A3 (en) Cancer therapy
WO2010052243A3 (en) Neurotensin-derived branched peptides and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10733653

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10733653

Country of ref document: EP

Kind code of ref document: A2